

Day 1: Thursday, February 6, 2025

Opening & keynote lecture 1 - 12:30 - 13:15

Room Schweitzer

Chairs: Anna Sureda (Spain) & Maria Themeli (The Netherlands)

Carl June (United States)
Keynote Lecture

Acute and chronic leukemias - 13:15 - 14:15

Room Schweitzer

Chairs: Ulrich Jäger (Austria) & Mette Hazenberg (The Netherlands)

Lessons learnt from AML
Nela Klein Gonzalez (Spain)

CAR-T cells for CLL: When? for whom?
Tanya Siddiqui (United States)

Adult ALL
Claire Roddie (United Kingdom)

Pediatric ALL
Peter Bader (Germany)

Coffee break - 14:15 - 14:45

Translational I: New frontiers and innovations - 14:45 - 16:15

Room Schweitzer

Chairs: Melita Irving (Switzerland) & Stanley Riddell (United States)

Special speaker
Stanley Riddell (United States)

Genome editing methods
Will Nyberg (Sweden)

Pooled CRISPR Screens: Reprogramming Therapeutic T Cells
Franziska Blaeschke (Germany)

Base editing to improve CAR T function
Judith Feucht (Germany)

Patient in focus: Delving into CAR T-Cell therapy accessibility challenges - 14:45 - 16:15

Room Cassin

Chairs: Jana Pelouchova (Czechia) & Natacha Bolanos (Spain)

Economic and organizational impact of the introduction of CAR-T-cell therapy
Speaker to be announced

Hospital exemption as a route for patient access to CAR-T therapy, enabling on-site manufacturing with greater flexibility and reduced costs for sustainable access
Manel Juan (Spain)

A patient's story of navigating cross border CAR-T cell therapy
Speaker to be announced

Recommendations for Health System Solutions
Liora Bowers (France)

Satellite symposium by BMS - 16:30 - 17:15

Room Schweitzer

Coffee break - 17:15 - 17:30

Oral Session 1 - 17:30 - 18:30

Room Schweitzer

CD19-DIRECTED CAR T CELL THERAPY IN 5 PATIENTS WITH REFRACTORY MULTIPLE SCLEROSIS
Johanna Richter (Germany)

RAPCABTAGENE AUTOLEUCCEL (YTB323) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): UPDATED RESULTS FROM A PHASE II CLINICAL TRIAL
Pere Barba (Spain)

REDUCTION IN EXTRAFOLLICULAR B CELL RESPONSES IN SLE PATIENTS AFTER CAR-T CELL THERAPY
Danae-Mona Nöthling (Germany)

THERAPY RELATED MYELOID NEOPLASM FOLLOWING CD19 DIRECTED CAR T CELLS FOR PATIENTS WITH B-CELL LYMPHOMA
Nicolas Gazeau (France)

AUTOCRINE GLUCOCORTICOID SIGNALING IN HORMONALLY ACTIVE CANCERS INDUCES ANTIGEN EXPRESSION FOR CAR-T CELL THERAPY

Marc Philipp Schauer (Germany)

IDENTIFICATION OF TUMOR-DERIVED MICRORNA125A AS A CATALYST FOR CAR-T CELL DYSFUNCTION IN B CELL MALIGNANCIES

Olivia Sirpilla (United States)

CAFFEINE-REGULATED MOLECULAR SWITCHES FOR FUNCTIONAL CONTROL OF CAR-T CELLS

Elise Sylvander (Austria)

DISTINCT PREFERENCES OF CD8+ AND CD4+ CAR-T CELLS FOR TRANSCRIPTION FACTOR ENHANCEMENT

Fabian Freitag (Germany)

CTLA-4-BASED ACTIVATION INDUCIBLE COSTIMULATORY RECEPTORS BESTOW CAR-T CELLS WITH SAFE, TUMOR-RESTRICTED, MULTI-TARGETING AND IMPROVED FUNCTIONAL FITNESS

Afroditi Katsarou (The Netherlands)

Chairs: Anna Sureda (Spain) & Maria Themeli (The Netherlands)**Keynote Lecture**

Monica Casucci (Italy)

Day 2: Friday, February 7, 2025

Clinical management session - 08:30 - 09:30

Room Schweitzer

Chairs: Chair: Ibrahim Yakoub-Agha (France)

Secondary malignancies after CAR T
Fabio Ciceri (Italy)

Infection complication after CAR T
Lidia Gil (Poland)

Cardiac complication after CAR T
Roni Shouval (United States)

European projects and networks - 08:30 - 09:30

Room Cassin

Chair: Jürgen Kuball (The Netherlands)

GoCART
Christian Chabannon (France)

T-FITNESS
Luca Gattinoni (Germany)

JOIN4ATMP
Speaker to be announced

AIDPATH
Carmen Sanges (Germany)

Nurses Track - Session 1 - 08:30 - 09:30

Room Curie

Chairs: Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

Opening comments
Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

Keynote lecture
Anna Sureda (Spain)

Keynote: Equity and access to CART
Nico Gagelmann (Germany)

Panel discussion
All speakers

Solid tumors - 09:30 - 10:30

Room Schweitzer

Chairs: To be announced

Special speaker: CAR T for Solid Tumors/Glioblastoma study
Michael Hudecek (Germany)

Treatment of solid tumors with NKG2D-based CAR T-cells
John Maher (United Kingdom)

Glioblastoma
Denis Migliorni (Switzerland)

Next-generation CAR-T cells for solid tumors and hematological malignancies
Sonia Guedan (Spain)

Nurses Track - Session 2: Fundamentals of cell and gene therapy - 08:30 - 09:30

Room Curie

Chairs: Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

Prehabilitation and rehabilitation - frailty, psychological and nutritional needs
Orla McCourt (United Kingdom)

Acute toxicity management
Ruth Clout (United Kingdom)

Late complications
Edoardo Campodonico (Italy)

Q&A
All speakers

Coffee break - 10:30 - 11:00

Tech Talk by Kyverna - 10:45 - 10:55

Gallery Schweitzer

Manufacturing and regulatory aspects - 11:00 - 12:30

Room Schweitzer

Chair: Ulrike Köhl (Germany)

GMP lentiviral manufacturing

Hugo Calderón (Spain)

Regulatory aspect

Attila Sebe (Germany)

Facilitating CAR T cell manufacturing: short-term CAR T cells and in vivo CAR delivery are moving into clinics

Christian Buchholtz (Germany)

Reimbursement of CAR T cells

Julio Delgado (Spain)

Panel discussion

All speakers

Clinical cases session - 11:00 - 12:00

Room Cassin

Chairs: Nico Gagelmann (Germany) & Koray Yalcin (Türkiye)

CAR T for autoimmune diseases

Fabian Müller (Germany)

Allogeneic CAR T

Reuben Benjamin (United Kingdom)

Gene therapy for hemoglobinopathies

Marina Cavazzana (France)

Pre/post poll questions

All speakers

Nurses Track - Session 3: Fundamentals of cell and gene therapy - 11:00 - 12:30

Room Curie

Chairs: Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

Update CART in hemato-oncology

Annalisa Ruggeri (Italy)

CART in autoimmune disease indications

Rafaella Greco (Italy)

Bispecifics - where do they fit?

Jeremy Deuel (Switzerland)

Gene therapy in hemoglobinopathy

Hilda Mekelenkamp (The Netherlands)

Lunch - 12:30 - 13:30

Satellite Symposium by Gilead - 13:00 - 13:45

Room Schweitzer

Translational II: CAR T designs, models and mechanisms - 14:00 - 15:30

Room Schweitzer

Chair: Sonia Guedan (Spain) & Maik Luu (Germany)

Mitochondrial transfer for adoptive T cell therapy

Luca Gattinoni (Germany)

Targeting metabolites / metabolic reprogramming

Mattias Wenes (Switzerland)

Engineered T cells in the tumor microenvironment

Melita Irving (Switzerland)

Models for CRS, ICANs, ICAHT

Robert Zeiser (Germany)

Chairs: Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

Wearables

Speaker to be announced

Remote monitoring CARAMA

Fanny Colin (France)

PPIE & CART service evaluatio

Britt Snoek (The Netherlands)

The last bridge - How patients experience CAR T-cell therapy and possible fields of action for nurses in the course of the treatment

Verena Leinemann (Austria)

Coffee break - 15:30 - 16:00

Industry theater by BMS - 15:35 - 15:55

Gallery Schweitzer

Keynote lecture 3 - 17:00 - 17:30

Room Schweitzer

Chairs: Anna Sureda (Spain) & Maria Themeli (The Netherlands)

Keynote Lecture

Martin Pule (United Kingdom)

New indications and other cell types - 17:30 - 19:00

Room Schweitzer

Chairs: Raffaella Greco (Italy) & Annalisa Ruggeri (Italy)

CAR-iNKT

Gianpetro Dotti (United States)

CAR- MSC

Saad Kenderian (United States)

CAR-treg

Chiara Bonini (Italy)

Round table

All speakers

European projects and networks: T2EVOLVE - 17:30 - 18:30

Room Cassin

Chair: Carmen Sanges (Germany)

Opening Remark

Speaker to be announced

Preclinical Models in T2EVOLVE

Speaker to be announced

Genotoxicity and Safety assessments in CAR-T Therapy

Speaker to be announced

Regulatory Harmonization and Adoption of Preclinical Models

Speaker to be announced

Nurses Track - Session 5: Shared decision making - Why it matters - 17:30 - 19:00

Room Curie

Chairs: Michelle Kenyon (United Kingdom) & Mairead Ni Chonghaile (Ireland)

LONGITUDINAL PATIENT REPORTED OUTCOMES (PROS) OF CAR T-CELL THERAPY AND THEIR IMPACT ON SURVIVAL

Anna Spanjaart (The Netherlands)

AN EXAMINATION OF PATIENT REPORTED SIDE-EFFECTS FOR CAR-T VERSUS OTHER THERAPIES IN PATIENTS WITH RELAPSED LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - AN ANALYSIS FROM THE LYMPHOMA COALITIONS 2024 GLOBAL PATIENT SURVEY

Steve Kallog (United States)

CARE-T: THE CAREGIVER'S PERSPECTIVE - AN EVALUATION OF SELF-PERCEIVED BURDEN AND IMPACT AMONGST CAREGIVERS OF CAR-T PATIENTS

Roberto Liu (The Netherlands)

What is shared decision making and why should we care

Jennifer Vidrine (United Kingdom)

Patient panel

All speakers

Day 3: Friday, February 7, 2025

International session - 08:30 - 09:30

Room Schweitzer

Chairs: Nico Gagelmann (Germany) & Koray Yalcin (Türkiye)

Slovenia

Matjaz Sever (Slovenia)

Türkiye

Siret Ratip (Türkiye)

India

Rahul Purwar (India)

Brazil

Nelson Hamershlak (Brazil)

Panel discussion

All speakers

Myeloma - 08:30 - 09:30

Room Schweitzer

Chairs: Sonja Zweegman (The Netherlands) & Hermann Einsele (Germany)

Special speaker

Jennifer Brudno (United States)

Academic CART-cells

Carlos Fernández de Larrea (Spain)

Commercial CART-cells

Maximilian Merz (Germany)

Bispecifics

Niels van de Donk (The Netherlands)

Optimizing Long Term Outcome of patients with B-cell lymphomas - 09:45 - 11:15

Room Cassin

Chair: Natacha Bolanos (Spain)

Long term outcome of CART cell therapy in patients with B-cell lymphomas (DLBCL, MCL, FL)

Andrea Kuhn (United Kingdom)

Sequencing therapies

Gloria Iacoboni (Spain)

Treatment after relapse

Emmanuel Bachy (France)

Optimized constructs and the potential of sequential CARs in LBCL

Anne Marijn Kramer (United States)

Panel discussion

All speakers

Coffee break - 11:15 - 11:30

Keynote lecture 4 - 11:30 - 12:00

Room Schweitzer

Chairs: Anna Sureda (Spain) & Maria Themeli (The Netherlands)

Keynote Lecture

Hinrich Abken (Germany)

Best abstracts & awards & closing - 12:00 - 13:00

Room Schweitzer

Chairs: Anna Sureda (Spain) & Maria Themeli (The Netherlands)

MICROBIOME-DERIVED METABOLITES GUIDE PATIENT OUTCOME PREDICTION AND CAR-T CELL ENGINEERING

Maik Lui (Germany)

PATIENT REPORTED OUTCOMES OF CAR-T CELL THERAPY: A EUROPEAN STUDY EVALUATING PATIENTS' EXPERIENCES, QUALITY OF LIFE AND UNMET CARE NEEDS - ZOOMING IN ON SOCIAL WELLBEING

Elise Pennings (The Netherlands)

FEASIBILITY OF A DECENTRALIZED ACADEMIC POINT-OF-CARE NETWORK FOR CAR-T CELL THERAPY

Mireia Bachiller (Spain)

GENERATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING P95HER2 IN SOLID TUMORS

Macarena Román Alonso (Spain)

Lunch to go - 13:00 - 13:30

Room Curie